Celltrion, Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 068270.KS | BIOCON.NS | REGN | 9995.HK | CHRS | 688382.SS | |
|---|---|---|---|---|---|---|
| Market cap | 49.02T | 592.87B | 96.28B | 40.23B | 131.36M | 8.38B |
| P/E (TTM) | — | 121.5 | 20.6 | 6.1 | — | — |
| Forward P/E | — | 33.3 | 13.2 | 46.7 | -1.3 | -43.8 |
| Price/book | — | 1.7 | 2.8 | 3.8 | 2.2 | 6.6 |
| Dividend yield | 0.36% | 0.15% | 0.40% | — | — | — |
| 1-year change | +20.07% | −10.58% | +43.87% | −19.94% | −42.95% | −48.70% |
| Today | +7.50% | +5.10% | −4.39% | +1.49% | +5.54% | +4.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 068270.KS news ›Celltrion Unveils World’s First Quadruple-Agonist Obesity Drug Candidate, CT-G32/SCO-940
Celltrion has unveiled preclinical data for CT-G32/SCO-940, a next-generation obesity drug candidate designed to simultaneously target four hormonal pathways: GLP-1, GIP, glucagon and amylin. The company aims to advance the candidate into…
Celltrion unveils promising results for four-target obesity drug
Published : Nov. 4, 2026 - 14:06:28 Celltrion has unveiled promising preclinical results for its next-generation obesity drug candidate, CT-G32/SCO-940, which outperformed a leading experimental weight-loss treatment in animal testing and…
More from 1 other outlet
Celltrion Unveils Preclinical Data on Quadruple-Action Obesity Drug
Animal Study Shows Greater Weight Loss Than Triple-Action Agent FDA Filing Due in February, First Patient Dosing Targeted for Q2 Celltrion (068270.KS) has released preclinical results for an obesity drug candidate that simultaneously…
Celltrion Unveils First Quadruple-Action Obesity Drug Candidate, Outperforming Retatrutide in Animal Study
Businesskorea Preclinical Results Show Greater Weight Loss at Same Dose, With Potential to Preserve Lean Mass Celltrion is accelerating the development of what it says is the world’s first qua
Celltrion's quadruple-action obesity drug outperforms triple agonist in animal tests
CT-G32/SCO-940 targets GLP-1, GIP, glucagon and amylin simultaneously — a world first Candidate shows greater weight loss than retatrutide at equal doses, with better lean mass preservation Primate PK data support once-weekly dosing; Phase…
Celltrion touts four-hormone obesity drug that tops triple-action rival
Celltrion claims CT-G32's four-pathway approach outperforms triple-agonists and preserves more lean mass, with FDA filing planned and first dosing eyed for Q2 2027 Celltrion said on the 4th that it presented preclinical study results for…
Celltrion's 4-hormone obesity drug beats Lilly's retatrutide on weight loss in rat study
Celltrion's experimental obesity drug targeting four hormonal pathways produced greater weight loss than Eli Lilly's triple-acting retatrutide in a rat study, the Korean biopharmaceutical company said Wednesday. The findings were presented…
Celltrion obesity drug — World's First Quad-Action Treatment Shows Superior Non-Clinical Results
Celltrion unveiled non-clinical results for its world-first quad-acting obesity drug candidate CT-G32, demonstrating superior weight loss effects. Celltrion obesity drug — World’s First Quad-Action Treatment Shows Superior Non-Clinical…
Celltrion Unveils Quadruple-Action Obesity Drug Candidate for First Time: "Weight Loss with Less Muscle Loss"
Published 04 Nov.2026 07:48(KST) Celltrion has for the first time disclosed preclinical results for an obesity drug candidate that simultaneously targets four hormonal pathways. In animal st
Celltrion unveils results for world's first 'quadruple-action' obesity drug, plans global trials next year
7:56 a.m. Nov 4, 2026 Celltrion said Wednesday that it has disclosed nonclinical research results for 'CT-G32/SCO-940,' a new drug candidate for an obesity treatment that simultaneously targets
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- en.sedaily.com10
- marketscreener.com10
- biz.chosun.com5
- finance.biggo.com5
- asiae.co.kr4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 61 articles, not a forecast.